DOCK2

Summary

DOCK2 (dedicator of cytokinesis 2, HGNC:2988) is a protein-coding gene on chromosome 5q35.1, encoding Dedicator of cytokinesis protein 2 (Q92608). Involved in cytoskeletal rearrangements required for lymphocyte migration in response of chemokines.

The protein encoded by this gene belongs to the CDM protein family. It is specifically expressed in hematopoietic cells and is predominantly expressed in peripheral blood leukocytes. The protein is involved in remodeling of the actin cytoskeleton required for lymphocyte migration in response to chemokine signaling. It activates members of the Rho family of GTPases, for example RAC1 and RAC2, by acting as a guanine nucleotide exchange factor (GEF) to exchange bound GDP for free GTP. Mutations in this gene result in immunodeficiency 40 (IMD40), a combined form of immunodeficiency that affects T cell number and function, also with variable defects in B cell and NK cell function.

Source: NCBI Gene 1794 — RefSeq curated summary.

At a glance

• Gene–disease (curated): DOCK2 deficiency (Definitive, ClinGen)
• GWAS associations: 8
• Clinical variants (ClinVar): 1,362 total — 18 pathogenic, 16 likely-pathogenic
• Phenotypes (HPO): 25
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_004946

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2988
Approved symbol	DOCK2
Name	dedicator of cytokinesis 2
Location	5q35.1
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0209
Ensembl gene	ENSG00000134516
Ensembl biotype	protein_coding
OMIM	603122
Entrez	1794

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 7 protein_coding, 6 protein_coding_CDS_not_defined, 6 retained_intron, 2 nonsense_mediated_decay

ENST00000433448, ENST00000518056, ENST00000519223, ENST00000519628, ENST00000519734, ENST00000519868, ENST00000520181, ENST00000520450, ENST00000520836, ENST00000520908, ENST00000522138, ENST00000522994, ENST00000523351, ENST00000523684, ENST00000524185, ENST00000648250, ENST00000648741, ENST00000696258, ENST00000961038, ENST00000961039, ENST00000961040

RefSeq mRNA: 1 — MANE Select: NM_004946 NM_004946

CCDS: CCDS4371

Canonical transcript exons

ENST00000520908 — 52 exons

Exon	Start	End
ENSE00000973113	169712120	169712223
ENSE00001026210	170082796	170083382
ENSE00002451054	169684196	169684350
ENSE00002519936	169681744	169681879
ENSE00002524482	169689252	169689333
ENSE00003463097	169840757	169840852
ENSE00003467991	170075947	170076084
ENSE00003469737	169716213	169716302
ENSE00003473908	170018960	170019108
ENSE00003491841	170056684	170056768
ENSE00003491954	170055305	170055386
ENSE00003497689	170047510	170047614
ENSE00003504009	169717384	169717484
ENSE00003508740	169669288	169669328
ENSE00003522864	169654403	169654486
ENSE00003523214	169761519	169761625
ENSE00003533330	169702303	169702427
ENSE00003535594	170008688	170008746
ENSE00003540017	169983068	169983166
ENSE00003541588	170081842	170081984
ENSE00003543247	170042013	170042132
ENSE00003553166	170067510	170067686
ENSE00003553188	170069137	170069220
ENSE00003558332	169985828	169985922
ENSE00003572346	170008497	170008597
ENSE00003575679	170027863	170027948
ENSE00003579330	169695803	169695938
ENSE00003581275	170078975	170079146
ENSE00003581737	169759705	169759775
ENSE00003599596	169747396	169747504
ENSE00003600684	170036515	170036555
ENSE00003606647	170041055	170041145
ENSE00003609473	169708169	169708267
ENSE00003613846	169670542	169670597
ENSE00003614819	169699382	169699458
ENSE00003617304	169674297	169674445
ENSE00003624292	169671078	169671174
ENSE00003624725	169698374	169698449
ENSE00003628721	169803058	169803206
ENSE00003649846	169700014	169700139
ENSE00003650131	170045816	170045905
ENSE00003653737	170050256	170050397
ENSE00003659124	169996086	169996164
ENSE00003666882	170077710	170077837
ENSE00003668719	170057580	170057666
ENSE00003668988	169718657	169718791
ENSE00003670407	170080163	170080283
ENSE00003676461	170034399	170034555
ENSE00003677913	169714360	169714457
ENSE00003727051	169711935	169712007
ENSE00003753052	169714028	169714211
ENSE00003839404	169637275	169637369

Expression profiles

Bgee: expression breadth ubiquitous, 216 present calls, max score 98.01.

FANTOM5 (CAGE): breadth broad, TPM avg 25.7386 / max 723.2375, expressed in 807 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
60092	24.9278	750
60093	0.6231	228
60094	0.1541	49
60095	0.0336	12

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
bone marrow cell	CL:0002092	98.01	gold quality
monocyte	CL:0000576	97.51	gold quality
mononuclear cell	CL:0000842	97.50	gold quality
leukocyte	CL:0000738	97.47	gold quality
granulocyte	CL:0000094	96.65	gold quality
blood	UBERON:0000178	96.21	gold quality
spleen	UBERON:0002106	94.46	gold quality
bone marrow	UBERON:0002371	93.94	gold quality
lymph node	UBERON:0000029	93.30	gold quality
vermiform appendix	UBERON:0001154	93.14	gold quality
colonic epithelium	UBERON:0000397	92.10	gold quality
trabecular bone tissue	UBERON:0002483	89.76	gold quality
thymus	UBERON:0002370	88.27	gold quality
tonsil	UBERON:0002372	88.01	gold quality
caecum	UBERON:0001153	87.77	gold quality
right lung	UBERON:0002167	86.67	gold quality
upper lobe of left lung	UBERON:0008952	86.65	gold quality
epithelium of nasopharynx	UBERON:0001951	86.09	gold quality
upper lobe of lung	UBERON:0008948	86.08	gold quality
superficial temporal artery	UBERON:0001614	84.29	gold quality
small intestine Peyer’s patch	UBERON:0003454	83.98	gold quality
lung	UBERON:0002048	83.91	gold quality
gall bladder	UBERON:0002110	83.24	gold quality
small intestine	UBERON:0002108	82.05	gold quality
rectum	UBERON:0001052	81.61	gold quality
decidua	UBERON:0002450	81.19	gold quality
amniotic fluid	UBERON:0000173	80.44	gold quality
lower lobe of lung	UBERON:0008949	80.41	silver quality
omental fat pad	UBERON:0010414	80.31	gold quality
peritoneum	UBERON:0002358	80.24	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	34.28
E-ANND-3	yes	13.77
E-CURD-119	yes	8.22
E-MTAB-6386	no	720.05
E-MTAB-6142	no	90.41

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

24 targeting DOCK2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-8080	99.82	67.52	1342
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-4743-3P	99.62	68.12	2095
HSA-MIR-548AV-5P	99.60	70.84	2107
HSA-MIR-548K	99.60	70.84	2107
HSA-MIR-4649-3P	99.56	66.90	1783
HSA-MIR-1252-3P	99.55	67.71	2862
HSA-MIR-8054	99.48	70.81	2084
HSA-MIR-4652-3P	99.33	70.02	2742
HSA-MIR-148A-5P	99.30	68.27	1141
HSA-MIR-6878-3P	99.24	64.23	920
HSA-MIR-3925-5P	99.21	67.90	1466
HSA-MIR-4279	99.19	66.70	2437
HSA-MIR-4738-3P	98.98	67.98	1846
HSA-MIR-5701	98.97	69.54	1502
HSA-MIR-3188	98.58	65.60	878
HSA-MIR-509-3P	98.12	67.25	612
HSA-MIR-4329	97.68	66.26	1003
HSA-MIR-148B-5P	97.29	66.30	992
HSA-MIR-6874-3P	97.29	66.34	975
HSA-MIR-3135A	96.41	65.30	494

Literature-anchored findings (GeneRIF, showing 37)

• DOCK2 mediates T cell receptor-induced activation of Rac2 and IL-2 transcription in jurkat cells (PMID:12176041)
• DOCK2 associates with CrkL and regulates Rac1 in human leukemia cell lines (PMID:12393632)
• the association of DOCK2 with ELMO1 is critical for DOCK2-mediated Rac activation, thereby suggesting that their association might be a therapeutic target for immunologic disorders caused by lymphocyte infiltration (PMID:12829596)
• Nef binds the DOCK2-ELMO1 complex to activate rac and inhibit lymphocyte chemotaxis (PMID:14737186)
• DOCK2 is needed for efficient chemokine-stimulated lymphocyte attachment to VCAM-1 under shear stress. (PMID:17015707)
• DOCK2 and DOCK9 specifically recognize Rac2 and Cdc42 through their switch 1 as well as beta2-beta3 regions and the mode of recognition via switch 1 appears to be conserved among diverse Rac-specific DHR-2 GEFs (PMID:18056264)
• PI3K and Src-ELMO-Dock2 pathways work in parallel to activate Rac2 and modulate chemotaxis in response to a CXCL8 gradient in neutrophils. (PMID:18662984)
• DOCK2 regulates microglial innate immunity independent of COX2 induction and DOCK2+ microglia are associated with human Alzheimer’s disease pathology. (PMID:19729484)
• This is the first report to clarify the prominent role of DOCK2 in hematopoietic malignancy. (PMID:20350533)
• prostate cancer cell lines differentially express phosphoinositide-3 kinase (PI3K) catalytic subunit isoforms and dedicator of cytokinesis 2 (PMID:20412587)
• Our results show CXCL13-mediated PCa cell invasion requires Akt and ERK12 activation and suggests a new role for DOCK2 in proliferation of hormone-refractory CXCR5-positive PCa cells. (PMID:21645150)
• The C-terminal Pro-rich tail of ELMO1 winds around the Src-homology 3 domain of DOCK2 to form an intermolecular 5-helix bundle. The entire regions of both DOCK2 a& ELMO1 assemble to create a rigid structure required for the DOCK2 & ELMO1 binding. (PMID:22331897)
• DOCK2 mutations are associated with esophageal adenocarcinoma. (PMID:23525077)
• DOCK2 is required for the normal T and B cell migration and signal transduction. (Review) (PMID:23911989)
• findings reveal a previously unknown, nonredundant role for Elmo1 in controlling Dock2 levels and Dock2-dependent T cell migration in primary lymphocytes. (PMID:24821968)
• Autosomal recessive DOCK2 deficiency is a new mendelian disorder with pleiotropic defects of hematopoietic and nonhematopoietic immunity. (PMID:26083206)
• DOCK2 is a potential therapeutic target for novel AML treatments, as this protein regulates the survival of leukemia cells with elevated FLT3 activity and sensitizes FLT3/ITD leukemic cells to conventional antileukemic agents. (PMID:27748370)
• Brazilian Amerindian ancestry compared to Asian, European, and African Genomes.SNPs within or proximal to CIITA (rs6498115), SMC6 (rs1834619), and KLHL29 (rs2288697) were most differentiated in the Amerindian-specific branch. SNPs in ADAMTS9 (rs7631391), DOCK2 (rs77594147), SLC28A1 (rs28649017), ARHGAP5 (rs7151991), and CIITA (rs45601437) in the Asian comparison. (PMID:28100790)
• demonstrated that CPP-conjugation approach is applicable to the development of novel anti-inflammatory drugs based on DOCK2 inhibition by investigating both cellular uptake and bioactivity (PMID:28284862)
• this study describes DOCK2 deficiency in a patient with Hyper IgM phenotype (PMID:29204803)
• This study reveals that the recruitment of DOCK2 may be critical for the capacity of Wnt5a to enhance CLL proliferation, which may contribute to the observed increased tendency for disease progression in patients who have CLL cells that express high levels of ROR1. (PMID:29678828)
• Findings demonstrated that overexpressed DOCK2 might involve in recruiting CD8(+) T lymphocytes and serve as a novel prognostic indicator and indicated a potential therapeutic strategy by restoring DOCK2 for CRC. (PMID:30076747)
• this study reports DOCK2 deficiency due to novel mutation affecting cellular immunity (PMID:30838481)
• The DOCK2 is a Rac activator critical for migration and activation of leukocytes. (PMID:31630188)
• miR-16 exhibits protective function in LPS-treated cardiomyocytes by targeting DOCK2 to repress cell apoptosis and exert anti-inflammatory effect. (PMID:32369253)
• Structure of the DOCK2-ELMO1 complex provides insights into regulation of the auto-inhibited state. (PMID:32651375)
• DOCK2 couples with LEF-1 to regulate B cell metabolism and memory response. (PMID:32703426)
• DOCK2 Deficiency Diagnosed 18 Years After Hematopoietic Stem Cell Transplantation. (PMID:33928462)
• DOCK2 Promotes Pleural Fibrosis by Modulating Mesothelial to Mesenchymal Transition. (PMID:34710342)
• DOCK2 regulates antifungal immunity by regulating RAC GTPase activity. (PMID:35079145)
• DOCK2 contributes to pulmonary fibrosis by promoting lung fibroblast to myofibroblast transition. (PMID:35584329)
• DOCK2 is involved in the host genetics and biology of severe COVID-19. (PMID:35940203)
• Extra-hematopoietic immunomodulatory role of the guanine-exchange factor DOCK2. (PMID:36380073)
• DOCK2 Promotes Asthma Development by Eliciting Airway Epithelial-Mesenchymal Transition. (PMID:36883952)
• Multiple Immune Defects in Two Patients with Novel DOCK2 Mutations Result in Recurrent Multiple Infection Including Live Attenuated Virus Vaccine. (PMID:36947335)
• DOCK2 Deficiency Attenuates Abdominal Aortic Aneurysm Formation-Brief Report. (PMID:37021575)
• DOCK2 Promotes Atherosclerosis by Mediating the Endothelial Cell Inflammatory Response. (PMID:37838011)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio		ENSDARG00000108038
danio_rerio		ENSDARG00000112944
danio_rerio		ENSDARG00000114649
danio_rerio		ENSDARG00000114803
danio_rerio		ENSDARG00000116994
mus_musculus	Dock2	ENSMUSG00000020143
rattus_norvegicus	Dock2	ENSRNOG00000006932
drosophila_melanogaster	mbc	FBGN0015513
caenorhabditis_elegans		WBGENE00000419

Paralogs (10): DOCK9 (ENSG00000088387), DOCK3 (ENSG00000088538), DOCK8 (ENSG00000107099), DOCK7 (ENSG00000116641), DOCK4 (ENSG00000128512), DOCK6 (ENSG00000130158), DOCK10 (ENSG00000135905), DOCK11 (ENSG00000147251), DOCK5 (ENSG00000147459), DOCK1 (ENSG00000150760)

Protein

Protein identifiers

Dedicator of cytokinesis protein 2 — Q92608 (reviewed: Q92608)

All UniProt accessions (6): A0A3B3IRS9, A0A3B3ISB1, A0A8Q3WL64, Q92608, E5RFJ0, H0YB76

UniProt curated annotations — full annotation on UniProt →

Function. Involved in cytoskeletal rearrangements required for lymphocyte migration in response of chemokines. Activates RAC1 and RAC2, but not CDC42, by functioning as a guanine nucleotide exchange factor (GEF), which exchanges bound GDP for free GTP. May also participate in IL2 transcriptional activation via the activation of RAC2.

Subunit / interactions. Homodimer. Interacts with RAC1 and RAC2. Interacts with CRKL and VAV. Interacts with CD3Z.

Subcellular location. Endomembrane system. Cytoplasm. Cytoskeleton.

Tissue specificity. Specifically expressed in hematopoietic cells. Highly expressed in peripheral blood leukocytes, and expressed at intermediate level in thymus and spleen. Expressed at very low level in the small intestine and colon.

Disease relevance. Immunodeficiency 40 (IMD40) [MIM:616433] A form of combined immunodeficiency characterized by lymphopenia, and defective T-cell, B-cell, and NK-cell responses. Patients suffer from severe invasive bacterial and viral infections in early childhood and may die without bone marrow transplantation. The disease is caused by variants affecting the gene represented in this entry.

Domain organisation. The DOCKER domain may mediate the GEF activity.

Miscellaneous. Splicing donor and acceptor sites between exon 6 and exon 7 are not canonical.

Similarity. Belongs to the DOCK family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q92608-1	1	yes
Q92608-2	2

RefSeq proteins (1): NP_004937* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001452	SH3_domain	Domain
IPR016024	ARM-type_fold	Homologous_superfamily
IPR026791	DOCK	Family
IPR026799	DHR2_DOCK2	Domain
IPR027007	C2_DOCK-type_domain	Domain
IPR027357	DOCKER_dom	Domain
IPR032376	DOCK_N	Domain
IPR035892	C2_domain_sf	Homologous_superfamily
IPR036028	SH3-like_dom_sf	Homologous_superfamily
IPR042455	DOCK_N_sub1	Homologous_superfamily
IPR043161	DOCK_C_lobe_A	Homologous_superfamily
IPR043162	DOCK_C_lobe_C	Homologous_superfamily
IPR046769	DOCKER_Lobe_A	Domain
IPR046770	DOCKER_Lobe_B	Domain
IPR046773	DOCKER_Lobe_C	Domain
IPR056372	TPR_DOCK	Domain

Pfam: PF06920, PF07653, PF14429, PF16172, PF20421, PF20422, PF23554

UniProt features (64 total): helix 23, strand 14, modified residue 8, splice variant 5, sequence variant 5, domain 3, turn 2, region of interest 2, chain 1, compositionally biased region 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
3A98	X-RAY DIFFRACTION	2.1
2YIN	X-RAY DIFFRACTION	2.7
3B13	X-RAY DIFFRACTION	3.01
6TGC	ELECTRON MICROSCOPY	4.1
6TGB	ELECTRON MICROSCOPY	5.5
2RQR	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q92608-F1	80.40	0.44

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (8): 738, 1685, 1706, 1731, 1784, 304, 588, 593

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-164944	Nef and signal transduction
R-HSA-6798695	Neutrophil degranulation
R-HSA-8980692	RHOA GTPase cycle
R-HSA-9013149	RAC1 GTPase cycle
R-HSA-9013404	RAC2 GTPase cycle
R-HSA-9013408	RHOG GTPase cycle
R-HSA-983231	Factors involved in megakaryocyte development and platelet production

MSigDB gene sets: 371 (showing top): GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_DN, GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, GOBP_PINOCYTOSIS, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_POSITIVE_REGULATION_OF_ENDOCYTOSIS, GOBP_ESTABLISHMENT_OR_MAINTENANCE_OF_CELL_POLARITY, GNF2_BNIP2, XU_GH1_AUTOCRINE_TARGETS_UP, GOCC_SECRETORY_GRANULE, GOBP_THYMIC_T_CELL_SELECTION, MODULE_45, GOBP_STRIATED_MUSCLE_CELL_DIFFERENTIATION, GOBP_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN, REACTOME_THE_ROLE_OF_NEF_IN_HIV_1_REPLICATION_AND_DISEASE_PATHOGENESIS

GO Biological Process (19): membrane raft polarization (GO:0001766), establishment of T cell polarity (GO:0001768), immunological synapse formation (GO:0001771), myeloid dendritic cell activation involved in immune response (GO:0002277), chemotaxis (GO:0006935), small GTPase-mediated signal transduction (GO:0007264), myoblast fusion (GO:0007520), cell migration (GO:0016477), actin cytoskeleton organization (GO:0030036), macropinocytosis (GO:0044351), positive thymic T cell selection (GO:0045059), negative thymic T cell selection (GO:0045060), alpha-beta T cell proliferation (GO:0046633), positive regulation of phagocytosis (GO:0050766), regulation of small GTPase mediated signal transduction (GO:0051056), cytoskeleton organization (GO:0007010), T cell proliferation (GO:0042098), T cell activation (GO:0042110), alpha-beta T cell activation (GO:0046631)

GO Molecular Function (5): guanyl-nucleotide exchange factor activity (GO:0005085), GTPase activator activity (GO:0005096), small GTPase binding (GO:0031267), T cell receptor binding (GO:0042608), protein binding (GO:0005515)

GO Cellular Component (9): extracellular region (GO:0005576), cytoplasm (GO:0005737), cytosol (GO:0005829), cytoskeleton (GO:0005856), plasma membrane (GO:0005886), membrane (GO:0016020), specific granule lumen (GO:0035580), extracellular exosome (GO:0070062), endomembrane system (GO:0012505)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
RHO GTPase cycle	4
The role of Nef in HIV-1 replication and disease pathogenesis	1
Innate Immune System	1
Hemostasis	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
T cell activation	3
lymphocyte activation	2
thymic T cell selection	2
GTPase regulator activity	2
membrane raft distribution	1
establishment of lymphocyte polarity	1
cell-cell recognition	1
myeloid dendritic cell activation	1
myeloid cell activation involved in immune response	1
immune response	1
response to chemical	1
taxis	1
intracellular signaling cassette	1
syncytium formation by cell-cell fusion	1
myotube differentiation	1
cell motility	1
cytoskeleton organization	1
actin filament-based process	1
pinocytosis	1
positive T cell selection	1
negative T cell selection	1
T cell proliferation	1
alpha-beta T cell activation	1
phagocytosis	1
positive regulation of endocytosis	1
regulation of phagocytosis	1
small GTPase-mediated signal transduction	1
regulation of intracellular signal transduction	1
organelle organization	1
lymphocyte proliferation	1
GTP binding	1
GDP binding	1
GTPase activity	1
enzyme activator activity	1
GTPase binding	1
signaling receptor binding	1
protein-containing complex binding	1
binding	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

2022 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DOCK2	ELMO1	Q92556	984
DOCK2	CRK	P46108	843
DOCK2	PLD2	O14939	822
DOCK2	RAC2	P15153	789
DOCK2	RABIF	P47224	711
DOCK2	DHX8	Q14562	669
DOCK2	TRAF6	Q9Y4K3	661
DOCK2	IRAK1	P51617	657
DOCK2	TRAF3	Q13114	645
DOCK2	DOCK11	Q5JSL3	642
DOCK2	LCP2	Q13094	633
DOCK2	CHUK	O15111	630
DOCK2	DHX37	Q8IY37	598
DOCK2	CXCL13	O43927	594
DOCK2	CCL19	Q99731	586

IntAct

176 interactions, top by confidence:

A	B	Type	Score
KRTAP5-9	DOCK2	psi-mi:“MI:0915”(physical association)	0.720
KRTAP10-8	DOCK2	psi-mi:“MI:0915”(physical association)	0.720
DOCK2	KHDRBS2	psi-mi:“MI:0915”(physical association)	0.720
KRT40	DOCK2	psi-mi:“MI:0915”(physical association)	0.720
MDFI	DOCK2	psi-mi:“MI:0915”(physical association)	0.720
DOCK2	KRTAP10-8	psi-mi:“MI:0915”(physical association)	0.720
KHDRBS2	DOCK2	psi-mi:“MI:0915”(physical association)	0.720
DOCK2	MDFI	psi-mi:“MI:0915”(physical association)	0.720
RAC1	DOCK2	psi-mi:“MI:0915”(physical association)	0.590
	DOCK2	psi-mi:“MI:0915”(physical association)	0.560
PLSCR1	DOCK2	psi-mi:“MI:0915”(physical association)	0.560
DOCK2	CCNDBP1	psi-mi:“MI:0915”(physical association)	0.560
DOCK2	TRIM23	psi-mi:“MI:0915”(physical association)	0.560
DOCK2	KRTAP10-9	psi-mi:“MI:0915”(physical association)	0.560
DOCK2	HNRNPK	psi-mi:“MI:0915”(physical association)	0.560
DOCK2	CALCOCO2	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (80): DOCK2 (Two-hybrid), HNRNPK (Two-hybrid), KRTAP5-9 (Two-hybrid), MDFI (Two-hybrid), PLSCR1 (Two-hybrid), CALCOCO2 (Two-hybrid), MTUS2 (Two-hybrid), CCNDBP1 (Two-hybrid), KRTAP9-2 (Two-hybrid), KRTAP9-4 (Two-hybrid), KRTAP4-2 (Two-hybrid), KRT40 (Two-hybrid), KHDRBS2 (Two-hybrid), KRTAP10-9 (Two-hybrid), KRTAP10-1 (Two-hybrid)

ESM2 similar proteins: A1A5P5, A6H690, A6NCM1, A7SK48, B2RY04, E7EXT2, O70481, P97393, P97564, Q12874, Q13017, Q14185, Q14738, Q1LXZ7, Q24087, Q2KI89, Q2TAA8, Q3SYG4, Q3U0M1, Q45GW3, Q4R8Y5, Q5GJ77, Q5R629, Q5ZL77, Q68F70, Q6AX60, Q6AXQ7, Q6NU25, Q7ZYV9, Q811G0, Q86XH1, Q8BUR4, Q8BWR8, Q8C3J5, Q8CDK3, Q8CIM8, Q8IUC4, Q8IWV7, Q8T773, Q92608

Diamond homologs: B2RY04, E7F1U2, P53281, P59764, Q14185, Q8BUR4, Q8C3J5, Q8CIQ7, Q8IZD9, Q8N1I0, Q92608, Q9H7D0, M0R4F8, Q09822, Q5TCX8, Q62662, Q6XZF7, Q8VDG6, Q91X43, Q922K9

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 70 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Keratinization	19	21.2×	1e-18

Disease & clinical

Clinical variants and AI predictions

ClinVar

1362 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	18
Likely pathogenic	16
Uncertain significance	542
Likely benign	654
Benign	65

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1065180	NM_004946.3(DOCK2):c.471-2A>G	Pathogenic
1070423	NM_004946.3(DOCK2):c.1348_1349del (p.Met450fs)	Pathogenic
1070656	NM_004946.3(DOCK2):c.4786C>T (p.Arg1596Ter)	Pathogenic
1071464	NM_004946.3(DOCK2):c.4858C>T (p.Arg1620Ter)	Pathogenic
1075139	NM_004946.3(DOCK2):c.316dup (p.Tyr106fs)	Pathogenic
1454578	NM_004946.3(DOCK2):c.149dup (p.His52fs)	Pathogenic
199258	NM_004946.3(DOCK2):c.3724_3725dup (p.Leu1244fs)	Pathogenic
199259	NM_004946.3(DOCK2):c.3970C>T (p.Gln1324Ter)	Pathogenic
199261	NM_004946.3(DOCK2):c.2253G>T (p.Arg751Ser)	Pathogenic
199262	NM_004946.3(DOCK2):c.2229_2230dup (p.Phe744fs)	Pathogenic
2154774	NM_004946.3(DOCK2):c.1847del (p.Gly616fs)	Pathogenic
2578989	NM_004946.3(DOCK2):c.1773dup (p.Leu592fs)	Pathogenic
2828268	NM_004946.3(DOCK2):c.650C>A (p.Ser217Ter)	Pathogenic
3726565	NM_004946.3(DOCK2):c.1330_1331del (p.Arg444fs)	Pathogenic
4682080	NM_004946.3(DOCK2):c.2037_2041del (p.Ile680fs)	Pathogenic
4728963	NM_004946.3(DOCK2):c.2721del (p.His907fs)	Pathogenic
4738028	NM_004946.3(DOCK2):c.1522C>T (p.Arg508Ter)	Pathogenic
835804	NM_004946.3(DOCK2):c.3633C>G (p.Tyr1211Ter)	Pathogenic
1028824	NM_004946.3(DOCK2):c.4729-2A>G	Likely pathogenic
1481167	NM_004946.3(DOCK2):c.3756+2T>C	Likely pathogenic
199260	NM_004946.3(DOCK2):c.3310C>T (p.Arg1104Trp)	Likely pathogenic
2008486	NM_004946.3(DOCK2):c.4072-1G>C	Likely pathogenic
2098039	NM_004946.3(DOCK2):c.1055+1G>A	Likely pathogenic
2584986	NM_004946.3(DOCK2):c.1055+1G>T	Likely pathogenic
2818527	NM_004946.3(DOCK2):c.5288-1G>T	Likely pathogenic
2832202	NM_004946.3(DOCK2):c.606+2T>G	Likely pathogenic
3064416	NM_004946.3(DOCK2):c.1057del	Likely pathogenic
3910720	NM_004946.3(DOCK2):c.106C>T (p.Arg36Ter)	Likely pathogenic
4081346	NM_004946.3(DOCK2):c.2615del (p.Lys872fs)	Likely pathogenic
565766	NM_004946.3(DOCK2):c.321+1G>A	Likely pathogenic

SpliceAI

9755 predictions. Top by Δscore:

Variant	Effect	Δscore
5:169637365:CGTGG:C	donor_loss	1.0000
5:169637368:GGGTA:G	donor_loss	1.0000
5:169637369:GGTA:G	donor_loss	1.0000
5:169637370:G:C	donor_loss	1.0000
5:169637370:G:GG	donor_gain	1.0000
5:169637371:T:G	donor_loss	1.0000
5:169654393:T:TA	acceptor_gain	1.0000
5:169654398:CACA:C	acceptor_loss	1.0000
5:169654399:A:AG	acceptor_gain	1.0000
5:169654400:C:G	acceptor_gain	1.0000
5:169654401:A:AG	acceptor_gain	1.0000
5:169654402:G:A	acceptor_loss	1.0000
5:169654402:G:GA	acceptor_gain	1.0000
5:169654402:GC:G	acceptor_gain	1.0000
5:169654402:GCC:G	acceptor_gain	1.0000
5:169654402:GCCA:G	acceptor_gain	1.0000
5:169654402:GCCAT:G	acceptor_gain	1.0000
5:169654487:G:GA	donor_loss	1.0000
5:169654487:G:GG	donor_gain	1.0000
5:169654488:T:A	donor_loss	1.0000
5:169674390:GA:G	donor_gain	1.0000
5:169674402:G:GT	donor_gain	1.0000
5:169674414:A:T	donor_gain	1.0000
5:169674418:TC:T	donor_gain	1.0000
5:169674446:G:GG	donor_gain	1.0000
5:169681838:G:GT	donor_gain	1.0000
5:169681880:G:GA	donor_loss	1.0000
5:169681881:TGAGC:T	donor_loss	1.0000
5:169684191:TTCA:T	acceptor_loss	1.0000
5:169684192:TCA:T	acceptor_loss	1.0000

AlphaMissense

12273 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:169671145:T:A	W98R	1.000
5:169671145:T:C	W98R	1.000
5:169671147:G:C	W98C	1.000
5:169671147:G:T	W98C	1.000
5:169674346:T:C	L124P	1.000
5:169695930:G:A	G324E	1.000
5:169702312:G:T	R423M	1.000
5:169708250:T:A	W489R	1.000
5:169708250:T:C	W489R	1.000
5:169714191:C:T	S608F	1.000
5:169714378:T:C	L621P	1.000
5:169714383:T:A	W623R	1.000
5:169714383:T:C	W623R	1.000
5:169716213:T:C	F648L	1.000
5:169716215:T:A	F648L	1.000
5:169716215:T:G	F648L	1.000
5:169716217:T:C	L649P	1.000
5:169716229:T:C	L653P	1.000
5:169717417:T:C	F689L	1.000
5:169717419:T:A	F689L	1.000
5:169717419:T:G	F689L	1.000
5:169717426:T:C	F692L	1.000
5:169717428:C:A	F692L	1.000
5:169717428:C:G	F692L	1.000
5:169717462:T:C	F704L	1.000
5:169717464:C:A	F704L	1.000
5:169717464:C:G	F704L	1.000
5:170008734:T:A	W1074R	1.000
5:170008734:T:C	W1074R	1.000
5:170019017:T:C	L1097P	1.000

dbSNP variants (sampled 300 via entrez): RS1000000794 (5:169823387 C>T), RS1000015028 (5:169862884 C>A,T), RS1000022789 (5:169941230 T>C), RS1000025409 (5:169945429 C>A), RS1000029073 (5:169676316 G>A), RS1000041994 (5:169962234 G>A), RS1000045812 (5:169651999 C>T), RS1000058915 (5:169859573 G>A), RS1000059470 (5:169658613 G>A), RS1000066412 (5:169736698 A>G), RS1000076334 (5:169737064 G>T), RS1000078095 (5:169722416 G>C), RS1000094646 (5:169640046 C>A), RS1000096640 (5:169819738 G>A), RS1000104170 (5:169779179 A>G)

Disease associations

OMIM: gene MIM:603122 | disease phenotypes: MIM:616433

GenCC curated gene-disease

Disease	Classification	Inheritance
DOCK2 deficiency	Definitive	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
DOCK2 deficiency	Definitive	AR

Mondo (2): DOCK2 deficiency (MONDO:0014637), prostate cancer (MONDO:0008315)

Orphanet (2): Combined immunodeficiency due to DOCK2 deficiency (Orphanet:447737), Familial prostate cancer (Orphanet:1331)

HPO phenotypes

25 total (25 of 25 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000403	Recurrent otitis media
HP:0001403	Macrovesicular hepatic steatosis
HP:0001510	Growth delay
HP:0001873	Thrombocytopenia
HP:0001954	Recurrent fever
HP:0002028	Chronic diarrhea
HP:0002113	Pulmonary infiltrates
HP:0002240	Hepatomegaly
HP:0002254	Intermittent diarrhea
HP:0003593	Infantile onset
HP:0003623	Neonatal onset
HP:0005387	Combined immunodeficiency
HP:0005403	Decreased total T cell count
HP:0006515	Interstitial pneumonitis
HP:0006532	Recurrent pneumonia
HP:0009098	Chronic oral candidiasis
HP:0011947	Respiratory tract infection
HP:0031402	Reduced antigen-specific T cell proliferation
HP:0031956	Elevated circulating aspartate aminotransferase concentration
HP:0031964	Elevated circulating alanine aminotransferase concentration
HP:0032170	Severe varicella zoster infection
HP:0032253	Eosinophilic granuloma
HP:0033164	Focal active colitis
HP:0100590	Rectal fistula

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST000189_11	Protein quantitative trait loci	1.000000e-06
GCST002481_3	Acne (severe)	3.000000e-06
GCST003649_8	Pneumococcal bacteremia	2.000000e-06
GCST005844_5	Placental abruption	5.000000e-06
GCST006085_106	Prostate cancer	2.000000e-08
GCST006430_2	Body mass index and waist-hip ratio (pleiotropy)	3.000000e-06
GCST012465_60	Bipolar disorder	3.000000e-11
GCST90013538_3	Coronary artery aneurysm in Kawasaki disease	2.000000e-06

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0005000	leptin measurement
EFO:1001925	pneumococcal bacteremia
EFO:0004340	body mass index
EFO:0004343	waist-hip ratio

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4105810 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

8 potent at pChembl≥5 of 9 total, top 8 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.22	IC50	6	nM	CHEMBL4101148
8.10	IC50	8	nM	CHEMBL4091844
7.96	IC50	11	nM	CHEMBL4064928
7.51	IC50	31	nM	CHEMBL4065267
7.46	IC50	35	nM	CHEMBL4101148
7.15	IC50	71	nM	CHEMBL4096227
7.02	IC50	95	nM	CHEMBL4069762
5.74	Kd	1822	nM	MOLIBRESIB

PubChem BioAssay actives

8 with measured affinity, of 15 total; 7 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2S)-2-[[(2S)-2-[[(2S)-2-[[(3S,9S,12S,15S,18S,21S,24R,29R,32S,35S)-24-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-15-(4-aminobutyl)-3,12-bis[(4-hydroxyphenyl)methyl]-9-(1H-imidazol-5-ylmethyl)-32-(1H-indol-3-ylmethyl)-18-methyl-2,5,8,11,14,17,20,23,31,34-decaoxo-21-propan-2-yl-26,27-dithia-1,4,7,10,13,16,19,22,30,33-decazabicyclo[33.3.0]octatriacontane-29-carbonyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoic acid	1481465: Inhibition of Rac1 binding to DOCK2 (unknown origin) by ELISA	ic50	0.0060	uM
(3S,9S,12S,15S,18S,21S,24R,29R,32S,35S)-24-acetamido-15-(4-aminobutyl)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-3,12-bis[(4-hydroxyphenyl)methyl]-9-(1H-imidazol-5-ylmethyl)-32-(1H-indol-3-ylmethyl)-18-methyl-2,5,8,11,14,17,20,23,31,34-decaoxo-21-propan-2-yl-26,27-dithia-1,4,7,10,13,16,19,22,30,33-decazabicyclo[33.3.0]octatriacontane-29-carboxamide	1481448: Inhibition of Rac1 binding to biotinylated DOCK2 (unknown origin) by ELISA	ic50	0.0080	uM
(3S,9S,12S,15S,18S,21S,24R,29R,32S,35S)-24-acetamido-15-(4-aminobutyl)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-3,12-bis[(4-hydroxyphenyl)methyl]-9-(1H-imidazol-5-ylmethyl)-32-(1H-indol-3-ylmethyl)-18-methyl-2,5,8,11,14,17,20,23,31,34-decaoxo-21-propan-2-yl-26,27-dithia-1,4,7,10,13,16,19,22,30,33-decazabicyclo[33.3.0]octatriacontane-29-carboxamide	1481448: Inhibition of Rac1 binding to biotinylated DOCK2 (unknown origin) by ELISA	ic50	0.0110	uM
(3S,9S,12S,15S,18S,21S,24R,29R,32S,35S)-24-acetamido-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-15-(4-aminobutyl)-3,12-bis[(4-hydroxyphenyl)methyl]-9-(1H-imidazol-5-ylmethyl)-32-(1H-indol-3-ylmethyl)-18-methyl-2,5,8,11,14,17,20,23,31,34-decaoxo-21-propan-2-yl-26,27-dithia-1,4,7,10,13,16,19,22,30,33-decazabicyclo[33.3.0]octatriacontane-29-carboxamide	1481448: Inhibition of Rac1 binding to biotinylated DOCK2 (unknown origin) by ELISA	ic50	0.0310	uM
(3S,9S,12S,15S,18S,21S,24R,29R,32S,35S)-24-acetamido-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-15-(4-aminobutyl)-3,12-bis[(4-hydroxyphenyl)methyl]-9-(1H-imidazol-5-ylmethyl)-32-(1H-indol-3-ylmethyl)-18-methyl-2,5,8,11,14,17,20,23,31,34-decaoxo-21-propan-2-yl-26,27-dithia-1,4,7,10,13,16,19,22,30,33-decazabicyclo[33.3.0]octatriacontane-29-carboxamide	1481448: Inhibition of Rac1 binding to biotinylated DOCK2 (unknown origin) by ELISA	ic50	0.0710	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(3S,9S,12S,15S,18S,21S,24R,29R,32S,35S)-24-acetamido-15-(4-aminobutyl)-3,12-bis[(4-hydroxyphenyl)methyl]-9-(1H-imidazol-5-ylmethyl)-32-(1H-indol-3-ylmethyl)-18-methyl-2,5,8,11,14,17,20,23,31,34-decaoxo-21-propan-2-yl-26,27-dithia-1,4,7,10,13,16,19,22,30,33-decazabicyclo[33.3.0]octatriacontane-29-carbonyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-N-[(2S,3S)-1-[[(2S)-6-amino-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]pentanediamide	1481448: Inhibition of Rac1 binding to biotinylated DOCK2 (unknown origin) by ELISA	ic50	0.0950	uM
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2179143: Binding affinity against DOCK2 (unknown origin) assessed as apparent dissociation constant incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	kd	1.8220	uM

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, increases methylation	3
Valproic Acid	affects expression, increases expression	3
entinostat	increases expression, affects cotreatment	2
(+)-JQ1 compound	decreases expression	2
Estradiol	decreases expression, affects cotreatment, increases expression	2
Smoke	increases expression	2
Aflatoxin B1	decreases methylation, increases methylation	2
aristolochic acid I	decreases expression	1
bisphenol A	decreases methylation	1
trichostatin A	increases expression	1
sodium bichromate	decreases expression	1
sodium arsenite	affects methylation	1
tetrabromobisphenol A	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
2,2’,4,4’,5-brominated diphenyl ether	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	decreases methylation	1
jinfukang	decreases expression, affects cotreatment	1
Arsenic	affects methylation	1
Calcitriol	decreases expression	1
Choline	affects expression	1
Cisplatin	affects cotreatment, decreases expression	1
Endosulfan	decreases expression	1
Formaldehyde	decreases expression	1
Lead	decreases expression	1
Nickel	increases expression	1
Rotenone	decreases expression	1
Silicon Dioxide	increases expression	1
Tobacco Smoke Pollution	increases expression	1

ChEMBL screening assays

11 unique, capped per target: 11 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4050561	Binding	Inhibition of DOCK2 (unknown origin) GEF activity	Investigation on cellular uptake and pharmacodynamics of DOCK2-inhibitory peptides conjugated with cell-penetrating peptides. — Bioorg Med Chem

Cellosaurus cell lines

3 cell lines: 3 induced pluripotent stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_C1VQ	PMUi002-A-1	Induced pluripotent stem cell	Male
CVCL_C1VR	PMUi002-A-2	Induced pluripotent stem cell	Male
CVCL_C1VS	PMUi002-A-3	Induced pluripotent stem cell	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer